Several lines of evidence suggest that the prototypical amphipathic transcriptional activators Gal4, Gcn4, and VP16 interact with the key coactivator Med15 (Gal11) during transcription initiation despite little sequence homology. Recent cross-linking data further reveal that at least two of the activators utilize the same binding surface within Med15 for transcriptional activation. To determine whether these three activators use a shared binding mechanism for Med15 recruitment, we characterized the thermodynamics and kinetics of Med15⅐activator⅐DNA complex formation by fluorescence titration and stopped-flow techniques. Combination of each activator⅐DNA complex with Med15 produced biphasic time courses. This is consistent with a minimum twostep binding mechanism composed of a bimolecular association step limited by diffusion, followed by a conformational change in the Med15⅐activator⅐DNA complex. Furthermore, the equilibrium constant for the conformational change (K 2 ) correlates with the ability of an activator to stimulate transcription. VP16, the most potent of the activators, has the largest K 2 value, whereas Gcn4, the least potent, has the smallest value. This correlation is consistent with a model in which transcriptional activation is regulated at least in part by the rearrangement of the Med15⅐activator⅐DNA ternary complex. These results are the first detailed kinetic characterization of the transcriptional activation machinery and provide a framework for the future design of potent transcriptional activators.
Several lines of evidence suggest that the prototypical amphipathic transcriptional activators Gal4, Gcn4, and VP16 interact with the key coactivator Med15 (Gal11) during transcription initiation despite little sequence homology. Recent cross-linking data further reveal that at least two of the activators utilize the same binding surface within Med15 for transcriptional activation. To determine whether these three activators use a shared binding mechanism for Med15 recruitment, we characterized the thermodynamics and kinetics of Med15⅐activator⅐DNA complex formation by fluorescence titration and stopped-flow techniques. Combination of each activator⅐DNA complex with Med15 produced biphasic time courses. This is consistent with a minimum twostep binding mechanism composed of a bimolecular association step limited by diffusion, followed by a conformational change in the Med15⅐activator⅐DNA complex. Furthermore, the equilibrium constant for the conformational change (K 2 ) correlates with the ability of an activator to stimulate transcription. VP16, the most potent of the activators, has the largest K 2 value, whereas Gcn4, the least potent, has the smallest value. This correlation is consistent with a model in which transcriptional activation is regulated at least in part by the rearrangement of the Med15⅐activator⅐DNA ternary complex. These results are the first detailed kinetic characterization of the transcriptional activation machinery and provide a framework for the future design of potent transcriptional activators.
The unique transcriptional signatures associated with human disease have spurred enormous efforts toward the discovery of artificial transcriptional regulators (1) (2) (3) (4) . These efforts are hampered by an incomplete understanding of the mechanism used by transcriptional activators to interact with and recruit the transcriptional machinery to a gene promoter (Fig. 1a) (5) . One domain of the activator, the transcriptional activation domain (TAD), 3 carries out this process, interacting with a variety of coactivators that remodel chromatin and mediate assembly of the preinitiation complex; these interactions regulate both the timing and extent of transcriptional activation (5, 6) .
Perhaps the three best characterized TADs are those of Gal4, Gcn4, and VP16. These are members of the largest class of activators, the amphipathic class, characterized by interspersed polar and hydrophobic amino acid residues in their TADs (Fig.  1b) . There is considerable evidence that these TADs share key mechanistic features despite little sequence homology, including a functionally important binding interaction with the coactivator Med15 (Gal11) (7) (8) (9) (10) (11) . Indeed, Gal4 and Gcn4 were recently shown to interact with the same binding site in the N terminus of Med15 (12) . Despite these similarities, the activators stimulate transcription to differing levels, with VP16-derived activators being the most potent and Gcn4 the least (for example, see supplemental Fig. S1 ).
Historically, comparisons of activator-coactivator interactions have centered on equilibrium binding measurements (apparent affinities), but these values are not a uniformly good predictor of function (13) (14) (15) (16) . Transcription is initiated through a series of coupled binding equilibria; and thus, a comparison of the kinetic and thermodynamic constants describing the individual steps of activator⅐coactivator complex formation should be more revealing of activator potency. However, efforts to kinetically characterize these interactions have produced conflicting models for the mechanism of complex formation (17) (18) (19) . In one example (17) , the interaction between the TAD of NF-B p65 and various coactivators was observed to be a single-step binding event, consistent with a simple co-localization function of the TAD. In another study, however, a two-step binding sequence was observed between the TAD of c-Myc and the coactivator TATA-binding protein (18) , suggesting that a conformational change in one or both of the partners may contribute to the function of the activator. In both of these examples, the time resolution of the experiment was within the seconds range, limiting the ability to detect rapid changes happening in the early stages of the interaction. An additional complication is that the kinetic studies to date have not examined activator-coactivator interactions under conditions in which the activator is bound to DNA.
Here, we used both fluorescence titration and fluorescence stopped-flow techniques to perform, for the first time, a transient kinetic analysis of three prototypical eukaryotic activators in a DNA-bound complex interacting with the key coactivator Med15. We find that all three activators follow a two-step binding mechanism, and the favorability of the conformational change step during complex formation correlates with their transcriptional activity in vivo. These results provide a framework for the future discovery of more potent transcriptional activators.
EXPERIMENTAL PROCEDURES
Plasmid Construction-Plasmids encoding maltose-binding protein (MBP)-tagged Gal4(1-100) fused to different TADs and GST-tagged Med15(1-345) were constructed and prepared by standard molecular cloning methods. Details are provided under supplemental "Materials and Methods."
Protein Expression-Although transcriptional activators and Med15 lacking a solubility tag can be expressed and isolated, we observed that the propensity of these constructs to aggregate rendered them unsuitable for stopped-flow experiments, consistent with previous observations (11, 20) . Taking advantage of the ability of TADs to bind and function when fused to a wide variety of proteins (for example, see Refs. 21-25), we incorporated an MBP tag at the N terminus of each activator to mitigate the aggregation propensity of the Gal4 DNA-binding domain (DBD). Thus, MBP-tagged activators and GST-tagged Med15 were expressed and isolated (for complete details, see supplemental "Materials and Methods") and used in binding and kinetic experiments. Gel filtration experiments (for details, see supplemental "Materials and Methods") indicated that GSTMed15 exists as a homodimer in solution over the range of concentrations used in the stopped-flow kinetic experiments. Thus, the indicated concentrations of Med15 represent those of the dimer.
Fluorescence Polarization Assays to Measure DNA AffinityThe 20-bp oligonucleotide 5Ј-TCC GGA GGA CTG TCC TCC GG-3Ј (26) labeled at the 5Ј-end with fluorescein or BODIPY FL was purchased from Invitrogen. The fluorescently labeled oligonucleotide was then annealed with an unlabeled complementary oligonucleotide (5Ј-GCC GGA GGA CAG TCC TCC GG-3Ј) in annealing buffer (10 mM HEPES (pH 7.5) and 150 mM NaCl) by heat denaturation for 7 min at 95°C, followed by cooling at room temperature for 30 min and at 4°C for 30 min.
Annealed fluorescein-labeled oligonucleotide (45 M) was diluted in DNA-binding buffer (20 mM HEPES (pH 7.5), 75 mM potassium acetate, 0.02 mM zinc sulfate, 4 mM magnesium acetate, 1 mM ␤-mercaptoethanol, 0.05 mM EDTA, 10% (v/v) glycerol, and 0.1 mg/ml BSA) (11) 
where a and x are the total concentrations of duplex DNA and dimeric activator, respectively; y is the observed polarization at any activator concentration; b is the maximum observed polarization value; and c is the minimum observed polarization value. Each data point in supplemental Fig. S3 is an average of three independent experiments with the indicated error (S.D.). Data analysis was performed using Origin software (OriginLab Corp.).
Fluorescence Titration Assays to Measure Med15 Affinity-GST-Med15(1-345) in storage buffer B (10 mM phosphatebuffered saline (pH 7.4) (Pierce), 10% (v/v) glycerol, 0.01% Nonidet P-40 substitute, and 1 mM DTT) was titrated (without exceeding a 5% volume increase) into the following solution to obtain the final Med15 concentrations indicated in Fig. 2 : 25 nM 5Ј-BODIPY FL-labeled double-stranded oligonucleotide preincubated with 100 nM dimeric activator in DNA-binding buffer. Under these conditions, 84% of the DNA is estimated to be complexed with activator, as calculated using Equation 1. The fluorescence intensity of BODIPY FL was monitored on an Eclipse spectrofluorometer (Varian Corp.) ( ex ϭ 500 nm, em ϭ 512 nm; 5-nm band-pass filter). The fluorescence intensity (F i ) was corrected for dilution effects and background fluorescence from the DNA⅐activator complex (F 0 ) such that ⌬F ϭ F i Ϫ F 0 (27) . The observed fluorescence fraction increase (⌬F/F 0 ) was plotted as a function of Med15 concentration, and a binding isotherm that accounts for ligand depletion (Equation 1; assuming a 1:1 binding model of DNA⅐activator complex to dimeric GST-Med15) was fit to the data using Origin 7.0 software to obtain the apparent equilibrium dissociation constant (K d ). The parameters a and x represent the total concentrations of DNA⅐activator complex and dimeric Med15, respectively; y is the observed relative fluorescence enhancement at any Med15 concentration; b is the maximum observed relative fluorescence enhancement value; and c is the minimum observed relative fluorescence enhancement value. Each data point in Fig. 2 is an average of three independent experiments with the indicated error (S.D.).
Fluorescence Stopped-flow Kinetic Experiments-Stoppedflow experiments were performed on a KinTek Model SF-2001 stopped-flow apparatus equipped with a 75-watt xenon arc lamp in two-syringe mode. 50 nM 5Ј-BODIPY FL-labeled double-stranded oligonucleotide precomplexed to 200 nM dimeric MBP-tagged Gal4 DBD fused to different TADs in DNA-binding buffer (25 and 100 nM after mixing) was mixed with an equal volume of GST-tagged Med15(1-345) (final concentration after mixing of 0.125-0.75 M for the homodimer) in DNAbinding buffer at 25°C. BODIPY FL was excited at 502 nm, and its emission was monitored at wavelengths Ͼ510 nm using a long-pass filter (Corion). All kinetic traces reported are an average of four to six independent determinations. The sum of exponentials was fit to the transient kinetic time courses, F(t) as in Equation 2 , to obtain the fluorescence amplitude (A) and the observed rate (k obs ) for each exponential phase,
where F(0) is the initial fluorescence intensity and t is time.
Two control experiments were performed to ensure that the fluorescence changes were from a Med15-TAD interaction: 50 nM 5Ј-BODIPY FL-labeled double-stranded oligonucleotide precomplexed to 200 nM dimeric MBP-tagged Gal4(1-100) was mixed with Med15 (0.375 M after mixing) at 25°C, and 5Ј-BODIPY FL-DNA⅐Gal4(1-100)-Gal4(840 -881) activator complex (5 nM after mixing) was mixed with dimeric GST (0.25 M after mixing) at 25°C. No time-dependent fluorescence enhancement was observed in either experiment (supplemental Fig. S4) .
Analysis of the time courses was performed using KinTek software, and the reported errors are the asymptotic standard errors. The dependence of the observed rates on Med15 concentration was analyzed using GraphPad Prism 4.0 software. Each kinetic constant reported in Table 1 is an average of two independent experiments with propagation of the experimental error.
Calculation of the Microscopic Kinetic Rate and Equilibrium
Constants for the Two-step Binding Models-Approximate solutions for k obs,1 and k obs,2 max in terms of the microscopic rate and equilibrium constants can be obtained from Equations
As described under the "Results" section, Table S2 .
KinTek Global Kinetic Explorer Analysis-Experimental fluorescence traces were fit with KinTek Global Kinetic Explorer (30) based on the Scheme A and Scheme B models (see Fig. 5 ), including parameters describing the fluorescence change in each step. The value of k 1 (k 4 in the case of Scheme B) was calculated from experimental data using Equation 3 (supplemental Equation 9 in the case of Scheme B) and served as a fixed constraint in the simulated fitting process. Values for Med15 concentrations and BODIPY FL-DNA⅐activator complex concentrations were set as the experimental values.
Because of the aggregation propensity of Med15 at higher concentrations, stopped-flow experiments were not carried out at saturating Med15 concentrations. To estimate the value of k max that gave the best description of the measured data are listed in Table 1 and were used in subsequent calculations. In each case, the value of k obs,2 max increased Յ50% from the measured value at the highest [Med15]. The [Med15] concentration dependence of k obs,2 is also consistent with the K 1/2 of the second phase amplitude (supplemental Fig. S6) .
Values of k 2 and k Ϫ2 were also calculated using Equations 5 and 8.
The calculated rate constants k 1 and k Ϫ1 in Table 2 , along with calculated values of k 2 and k Ϫ2 , were used to simulate experimental traces based on the Scheme A model (see Fig. 5 ), allowing the change in fluorescence to vary for each step.
RESULTS

DNA-binding Properties
Are Independent of TAD Composition-In our experimental design, each TAD was characterized in the context of a DNA-bound activator to mimic its presentation at a gene promoter. For this purpose, the well studied Gal4(1-100) DBD fused to the TADs of Gal4 (residues 840 -881), Gcn4 (residues 107-144), and VP16 (residues 456 -490) was expressed and purified from bacteria. Each DBD-TAD fusion protein exhibited an identical binding affinity (K d ϭ 15 Ϯ 5 nM) for a fluorescently labeled consensus DNA-binding site composed of two half-sites as determined by fluorescence polarization experiments (supplemental Fig. S3) ; these K d values are consistent with those previously reported for Gal4(1-100) (31) . Thus, the DNA-binding function was independent of the TAD, indicative of the modular architecture of most transcriptional activators (5, 6) .
Binding Affinity of the Activator⅐DNA Complex for the Coactivator Med15-We next examined the affinity of the activator⅐DNA complex for the coactivator Med15 under equilibrium conditions. Med15 resides in the multicomponent Mediator complex thought to function as a conduit between DNA-bound transcriptional regulators and RNA polymerase II (32) (33) (34) . Both genetic and biochemical studies suggest that Med15 is a key target of amphipathic activators. Recent crosslinking experiments localized functionally important binding interactions within the N terminus of this protein (12) . Furthermore, decreases in transcription were observed for Gal4, VP16, and Gcn4-derived activators in Med15(1-345)-deleted strains compared with wild-type yeast as measured by ␤-galactosidase assays (for example, see supplemental Fig. S1 ). Consistent with these data, titration of micromolar concentrations of GSTtagged Med15(1-345) (11, 20) into a solution of preformed BODIPY FL-DNA⅐Gal4(1-100)-TAD complex produced a hyperbolic increase in fluorescence (Fig. 2) . The three activators exhibited similar apparent dissociation constants (K d(app) ) with Med15 of between 100 and 320 nM (Table 1) ; the affinity of the VP16-and Gal4-derived activators was ϳ2-fold higher than that of the Gcn4 activator.
Transient-state Analysis of Activator-Coactivator Association Reveals Biphasic Binding Kinetics-The association kinetics for formation of the BODIPY FL-DNA⅐activator⅐Med15
complex were assessed by mixing Med15 with the BODIPY FL-DNA⅐activator complex in a stopped-flow fluorescence spectrometer under pseudo-first-order conditions and measuring the time-dependent changes in fluorescence. Gal4, Gcn4, and VP16 all exhibited an increase in fluorescence over time at each Med15 concentration tested, producing time courses that are biphasic and best fit by a double exponential at both 25°C (Fig. 3 ) and 16°C (supplemental Fig. S5 ). Analogous experiments performed by mixing DNA-bound Gal4(1-100) lacking a TAD with Med15 or mixing the DNA⅐activator complexes with GST produced no increase in fluorescence over the background (supplemental Fig. S4 ), indicating that the fluorescence change reports only the Med15-TAD interaction. The observed rate for the faster phase (k obs,1 ) was linearly dependent on the Med15 concentration for all three activator constructs, with a positive slope reflecting an apparent bimolecular association rate constant that varied from 9 ϫ 10 6 M Ϫ1 s Ϫ1 for Gal4 to 66 ϫ 10 6 M Ϫ1 s Ϫ1 for Gcn4 ( Fig. 4a and Table 1) . These values are in the range of diffusion-controlled processes (10 6 -10 7 M Ϫ1 s Ϫ1 ) (35) , suggesting that this step is the binding of Med15 to the activator⅐DNA complex. 4 The observed rates for the slower phase (k obs,2 ) (Fig. 4b) were dependent on the identity of the TAD (Fig. 4b and Table 1 ) and had a modest dependence on the concentration of Med15. The higher errors in the rates were due to the smaller amplitude of this slower phase. Lowering the temperature to 16°C resulted in a more prominent slower phase with rates that were decreased by 2-4-fold (supplemental Fig. S5 ).
These biphasic binding kinetics suggest a minimum kinetic mechanism that requires a two-step binding process. The fact that the rate of the slow phase was sensitive to temperature and to the simulated traces of the time-dependent formation of (DNA⅐activator⅐Med15) ϩ ((DNA⅐activator)*⅐Med15). In these simulations, the microscopic rate constants k 1 and k Ϫ1 ( did not exhibit a linear dependence on Med15 concentration ( Fig. 4b and supplemental Fig. S5 ) is consistent with the occurrence of a unimolecular conformational change step that occurs either after or before the bimolecular binding step (Schemes A and B, respectively, in Fig. 5 ). Additionally, the relative amplitudes of the two phases depended on the TAD of each activator (supplemental Fig. S7 ), consistent with this kinetic mechanism. Microscopic Kinetic Rate Constants Calculated for the Twostep Binding Model-The full solutions to the rate equations describing the two limiting binding mechanisms shown in Fig. 5 have been published previously (29) . The microscopic rate constants included in k obs,1 and k obs,2 can be approximated for each of the limiting pathways (Schemes A and B in Fig. 5 ) according to Equations 3-8 and supplemental Equations 9 -14, respectively (see "Experimental Procedures" and supplemental "Materials and Methods") (28) . Using these equations, the microscopic rate (k 1 and k Ϫ1 ) and equilibrium (K 1 ) constants for Scheme A, the binding mechanism in which a conformational change occurs after the bimolecular collision step, were calculated from the experimentally obtained values presented in Table 1 Table 2 . The values of k 2 and k Ϫ2 were also estimated (from k obs,2 max and K 2 ) for use in simulation studies presented in the following section. 5 Similarly, the microscopic rate and equilibrium constants for the binding mechanism presented in Scheme B, in which a conformational change occurs before the bimolecular collision step, are presented in supplemental Table S2 .
Global Kinetic Simulation Studies Suggest That Med15 Binding Precedes the Conformational Change-The data from individual stopped-flow experiments were globally analyzed using KinTek Global Kinetic Explorer with either the Scheme A or Scheme B model. The values of k 1 (Scheme A) or k 4 (Scheme B) were used as a constraint in these fits (Table 2 and supplemental  Table S2 ). Scheme A provided a modest to significantly better fit to the experimental data relative to Scheme B. 6 This suggests that a model in which the conformational change step occurs after the formation of the Med15⅐activator⅐DNA complex (Scheme A) is the more appropriate framework for describing this interaction.
To examine whether the limiting kinetic models are sufficient to describe the data, the transient kinetic curves were simulated using the rate constants for Scheme A (calculated by Equations 3-8; k 1 and k Ϫ1 (Table 2 ) as well as k 2 and k Ϫ2 ) as fixed parameters and allowing the change in fluorescence for each step to vary. The simulated curves agree well with the experimental stopped-flow traces (Fig. 6) . In comparing the three activators, the traces show a decrease in amplitude of the slow phase relative to the fast phase (supplemental Fig. S7) , consistent with the decreasing value of K 2 .
In summary, these simulations demonstrate that the data are best described by a scheme in which the observed conformational change occurs after the DNA-bound activator associates with Med15 (Scheme A in Fig. 5 ) (36 -38) . Consistent with this mechanism, structural studies performed on the isolated TADs of Gal4 and VP16 have shown them to be mostly unstructured in the absence of their binding partners, but helical in the bound form (39 -42) , and this behavior is characteristic of other isolated TADs of this class as well (36, (43) (44) (45) .
DISCUSSION
Here, for the first time, we have reported the transient kinetics of prototypical activator⅐DNA complexes interacting with the key coactivator Med15. Importantly, these data demonstrate that three distinct amphipathic activators interact with Med15 via a two-step binding mechanism that includes a conformational change. The limiting kinetic pathways for this twostep mechanism differ only in the order of the two steps (Schemes A and B in Fig. 5 ). Although our kinetic data do not absolutely distinguish these mechanisms, Scheme A, in which a conformational change step occurs after the association step, is most consistent with the high value of the bimolecular rate constant, the simulation data, and previous data demonstrating the formation of helical structure in the isolated TADs of Gal4 and VP16 upon interaction with their binding partners (39 -42) . We therefore further analyzed these data using this kinetic mechanism. 5 Although k 1 and k Ϫ1 were calculated directly from the kinetic data, to obtain k 2 and k Ϫ2 , one must use the K d determined through equilibrium binding measurements (Fig. 2 ) that were carried out under conditions that differed slightly. Experiments to directly measure the off-rate (k off ) to better define k 2 and k Ϫ2 were unsuccessful due to aggregation propensities of the TADs at the high concentrations needed for these experiments. 6 Goodness of fit was determined by values of 2 /degrees of freedom: for Scheme A, 1.07 (VP16), 1.06 (Gal4), and 1.07 (Gcn4); and for Scheme B, 1.14 (VP16), 1.52, (Gal4), and 1.14 (Gcn4). FIGURE 5. Schematics of the two limiting binding models for DNA-bound activators interacting with Med15. In Scheme A, the conformational change occurs after an initial binding event, whereas in Scheme B, the DNAbound activator undergoes a conformational change prior to associating with Med15. The pathway used by an activator may change depending upon the concentration(s) of the individual binding partners. A comparison of the measured rate and equilibrium constants determined for Scheme A revealed trends that provide insight into the differential activity of the three activators Gal4, Gcn4, and VP16. In general, the TAD activity correlates with a more favorable K d(app) for Med15 (VP16 Ͼ Gal4 Ͼ Gcn4) ( Fig.  7 and Table 1 ). Analysis of the thermodynamics of the individual steps within the kinetic mechanism revealed that this correlation is governed not by the equilibrium constant for the initial bimolecular association step (K 1 ), which is invariant among all three TADs, but by the value of the subsequent conformational change step (K 2 ) (Fig. 7) . In particular, a greater K 2 value (more favorable conformational change step) correlates with a more active TAD. To play an important role in regulating activation by varying the concentration of the active (DNA⅐activator)*⅐Med15 complex, the conformational change must be unfavorable for some or all of the TADs. Consistent with this model, for VP16, the equilibrium constant for the conformational change is moderately favorable (K 2 ϭ 2.3), indicating that at saturating [Med15], Ͼ70% of the DNA⅐VP16⅐Med15 complex forms the active conformation. In contrast, the conformational change is unfavorable for Gcn4 (K 2 ϭ 0.12), indicating that only ϳ10% (all values were calculated within 20% propagated error.) Experimental data and simulated traces reflect a change in fluorescence intensity. The three TADs are offset by 1.0 (VP16), 0.5 (Gal4), and 0 (Gcn4) arbitrary units (a.u.) for clarity purposes. of the DNA⅐Gcn4⅐Med15 complex is in the active conformation. Although less well defined by the data, a similar trend is observed for kinetic partitioning between the conformational change and dissociation of Med15 (k 2 /k Ϫ1 ); the most active TAD, VP16, has the largest value of k 2 and the largest partition ratio, indicating that the intermediate DNA⅐activator⅐Med15 complex undergoes the conformational change the fastest of the three activators and has the highest partition ratio to form the new conformer relative to dissociation.
In conjunction with structural evidence that isolated TADs of this class are intrinsically disordered and undergo structural enhancement upon interaction with a target protein (6, 46, 47) , we hypothesize that the different degree of transient structure inherent to each TAD may play a role in the differences observed in the kinetics during the conformational change step to form the final DNA⅐activator⅐Med15 complexes (k 2 ). For example, the faster conformational change observed for VP16 compared with that of Gal4 and Gcn4 may be attributed to the fact that residues 472-479 within the isolated VP16 TAD have a propensity to form a relatively well defined helix (48) , although additional structural studies will be required to refine this model. Furthermore, it is important to note that although the current method of detection through an enhancement in fluorescence of a probe on the DNA limits our abilities to determine which component(s) within the complex is undergoing the conformational change, future studies in which the probes are placed at the TAD target interface will provide additional details in this regard.
Finally, the favorability of the conformational change (K 2 ), which is encoded in the primary amino acid sequence of each TAD by the particular arrangement of the acidic, polar, and hydrophobic amino acid residues (49), may explain why three TADs that target the same protein via a shared binding mechanism can lead to differences in the assembly of the preinitiation complex and transcriptional output. Thus, the identification of artificial TADs with additional structural stability may lead to artificial activators with enhanced transcriptional activity.
